On the transparency front, it was a busy summer for the European Federation of Pharmaceutical Industries and Associations (EFPIA). In the wake of recent ‘Sunshine’ legislation in France and other EU countries, and pending transparency trials before the Court of Justice of the European Union (CJEU), EFPIA adopted no less than two brand new transparency documents: a Disclosure – ‘Sunshine’ – Code and joint Principles for Responsible Clinical Trial Sharing. It also significantly strengthened the advertisement commitments in its existing Code on Interactions with HCPs.
Members-only access
To access the full resource, you must be a member. Already a member? Login to unlock.
Login
Not an ACC member?
Gain access to a comprehensive collection of global resources for in-house counsel
Sign up for a 30-day trial
Region:
France
The information in any resource collected in this virtual library should not be construed as legal advice or legal opinion on specific facts and should not be considered representative of the views of its authors, its sponsors, and/or ACC. These resources are not intended as a definitive statement on the subject addressed. Rather, they are intended to serve as a tool providing practical advice and references for the busy in-house practitioner and other readers.